<International Circulation>:  One of the benefits of the novel anticoagulants is that they may be simpler to administer， how is this the case?
   《国际循环》：新的抗凝药物的一个好处是他们更容易监测，这种情况是怎样的？
    Prof. Weitz: They are definitely simpler to administer because they don’t require the monitoring and dose adjustments.  We have data， not so specifically for the VTE setting although they are at least as effective and safe for VTE as warfarin， and there is some indication that they may be safer than warfarin， but if we take the population overall it is clear that there is less intracranial bleeding.  It is probably not as common in the VTE population as in the AF population because they are younger.
    Weitz教授:他们的检测、处理可能很简单，因为不需要监测以及剂量调整。我们有数据，不是针对性的关于VTE的情况，尽管他们很有效并且像华法林治疗VTE那样安全，还有一些迹象表明，他们可能比华法林安全，但是如果我们考虑全部的人群，有一点很清楚即他们颅内出血的发生率是低的。像房颤人群那样，VTE人群因为比较年轻，很可能不那么常见。